Navigation Links
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Date:2/4/2008

EMEA).

One-year findings from one of two ustekinumab Phase 3 trials were presented for the first time at the annual meeting of the American Academy of Dermatology this past Saturday, February 2.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease, which results from the overproduction of skin cells resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that 125 million people worldwide have psoriasis, including two percent of both the U.S. and European populations, or some 7.5 million Americans and 10 million Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe.(1)

About Ustekinumab

Ustekinumab is a new, human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis, and is being investigated as an infrequently administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in regulating the immune system and that are also believed to play a role in immune-mediated inflammatory disorders.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies have exclusive marketing rights in all countries outside of the United States.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (HZDR), the Vienna University of Technology and the ... nearly perfect semiconductor crystals into a silicon nanowire. ... very fast and multi-functional processing units can be ... The research results will be published in the ... considered the cornerstone of future chip technology, but ...
(Date:7/23/2014)... 2014  Having the right people at the table ... business growth and achieving clinical and operational goals. The ... Summit, July 20-22, 2014, in San Diego ... and healthcare experts discussing how partnerships have positively impacted ... & Chief Executive Officer of Cape Regional Medical Center ...
(Date:7/23/2014)... - BioAmber Inc. (NYSE: BIOA ), ... that the underwriters of its common stock offering ... additional 420,000 shares of common stock at the ... underwriting discounts and commissions, in connection with its ... of common stock, bringing the expected net proceeds ...
(Date:7/23/2014)... , July 23, 2014 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... Group Limited ("Cordlife"), a multi-product healthcare company catering to the mother ... forces in assisting patients across the PRC, Singapore ... , India , the Philippines ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... Its Kind Instant Dissolve Powder Antacid Delivers Faster Relief, ... Increased Convenience and Great Taste, ... a $20 million integrated marketing campaign,for the new TUMS(R) QuikPak(TM), ... TUMS brand. The QuikPak campaign, part of,a larger new "Bring ...
... Follow, FREDERICK, Md., April 21 ... for ActiPatch(TM) for,kidney-compromised patients. BioElectronics Corporation, (Pink ... revolutionary drug-free,anti-inflammatory patch which accelerates healing., ... ibuprofen,(Advil, Motrin, Nuprin) and Naproxen (Aleve, Anaprox, ...
... DUBLIN, Calif., April 21 SuperGen Inc.,(Nasdaq: ... discovery, rapid,development and commercialization of therapies for solid ... release its 2008,first quarter financial results on Monday, ... of the Company,s financial results and,any revised outlook ...
Cached Biology Technology:New TUMS(R) QuikPak(TM) Campaign Offers Innovative Heartburn Relief with a Little Help from the Jetsons 2Maryland Approves Medicaid Reimbursement for ActiPatch(R) 2SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008 2
(Date:7/23/2014)... fur seals, alongside decades of in-depth monitoring, has ... change on a population of top-predators. Published in ... that the seals have significantly altered in accordance ... with climate conditions. Despite a shift in the ... passing down through generations, leaving the population in ...
(Date:7/23/2014)... issued a high health risk warning for Yellowknife and ... due to forest fires. In the image taken ... along normal wind patterns. Fire is an obvious ... is not quite so obvious and its effects are ... fire (forest, brush, crop, structure, tires, waste or wood ...
(Date:7/23/2014)... people around the world have no access to clean ... 3.4 million people die from water-related diseases every year. ... making a contribution to solving this problem. Working with ... of the Functional Materials Laboratory, the 23-year-old spent a ... , "What makes our DrinkPure filter unique is that ...
Breaking Biology News(10 mins):Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3ETH student develops filter for clean water around the world 2
... leaf has revealed the oldest known evidence of a macabre ... to turn them into zombies. The discovery has been ... Hughes, from the University of Exeter, who studies parasites that ... manner of animals are susceptible to the often deadly body ...
... from Mount Sinai School of Medicine have enhanced our ... conversion, the process in which food is converted into ... scientists gain atomic-level insight into how organisms synthesize their ... published in the August issue of PLoS Biology ...
... Mont. -- Researchers at Montana State University have ... for treating antibiotic resistant infections, fungal infections and viral ... to study such compounds. The technologies are ... The first technology involves an existing clinical drug ...
Cached Biology News:Fossil reveals 48-million-year history of zombie ants 2Mount Sinai researchers discover new mechanism behind cellular energy conversion 2Montana State University offers 6 new biomedical technologies for licensing 2Montana State University offers 6 new biomedical technologies for licensing 3Montana State University offers 6 new biomedical technologies for licensing 4
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
... degradation is critical to the maintenance ... regulatory proteins as important and diverse ... heat shock and stress response, antigen ... and ion channels, cell cycle regulation, ...
... digital scanner serves as the spot-picking platform. ... standard rack positions on the tray, leaving ... plates on the remaining two racks.,The software ... by mouse-click on the scanned gel image. ...
...
Biology Products: